Evidence map›Paper›PMID 41313360›Full record

ArticleClinical oral investigations2025

Comparison of growth factor concentrations in platelet-rich fibrin biomaterial in different systemic diseases.

İsmail Kuybu, Hilal Alan, Mehmet Sait Şimşek

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Effect of concentrated growth factors in guided tissue regeneration for the treatment of mandibular molar furcation lesions].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026
    Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

İsmail KuybuPrivate Clinic, Kahramanmaraş, Turkey.
Hilal AlanPrivate Clinic, Malatya, Turkey.
Mehmet Sait ŞimşekDepartment of Oral and Maxillofacial Surgery, İnönü University, Malatya, Turkey. sait.simsek@inonu.edu.tr.

Funding

Scientific Research Projects Unit of İnönü University 1814
6 · The paper itself

Abstract

objectiveThis study aimed to evaluate and compare the concentrations of Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), and Transforming Growth Factor (TGF) in platelet-rich fibrin (PRF) biomaterials obtained from individuals with various systemic diseases. MATERIALS AND

methodsA total of 65 individuals were included and divided into five groups: healthy controls (n = 13), patients diagnosed with diabetes (n = 13), patients receiving bisphosphonate therapy (n = 13), patients using immunomodulatory drugs (n = 13), and patients diagnosed with hepatitis (n = 13). PRF samples were collected from each participant and analyzed in a biochemistry laboratory using ELISA kits specific to PDGF, VEGF, and TGF. The growth factor concentrations were statistically compared across the groups.

resultsThe highest mean concentration of PDGF was observed in the hepatitis group. The highest mean concentrations of VEGF and TGF were found in patients using immunomodulatory drugs. However, the differences in growth factor concentrations among the groups were not statistically significant.

conclusionPRF is an effective biomaterial widely used in dentistry due to its rich content of growth factors. While no statistically significant differences were found in growth factor concentrations among individuals with different systemic conditions, a notable increase in these levels was observed in certain disease groups. These findings suggest that systemic diseases may influence the biological composition of PRF, warranting further investigation.

Indexed as

Biocompatible MaterialsIntercellular Signaling Peptides and ProteinsPlatelet-Derived Growth FactorPlatelet-Rich FibrinVascular Endothelial Growth Factor AAdultAgedCase-Control StudiesDiabetes MellitusEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedBiocompatible MaterialsIntercellular Signaling Peptides and ProteinsPlatelet-Derived Growth FactorVascular Endothelial Growth Factor ABiomarkersEnzyme-linked immunosorbent assayGrowth factorsPlatelet-rich fibrinSystemic diseases

Identifiers

PMID41313360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.